Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New 20-Strain pneumonia vaccine tested in chinese seniors

NCT ID NCT07019909

Vaccine Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new 20-valent pneumococcal vaccine (20vPnC) against an existing 13-valent vaccine in 400 adults aged 50 and older in China who had never received a pneumococcal vaccine. The goal was to check safety and immune response. Results will help decide if the broader-coverage vaccine is safe enough for larger trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
20-valent pneumococcal conjugate vaccine (20vPnC) and 13-valent pneumococcal conjugate vaccine (13vPnC)
What this could lead to
If successful, this could lead to a new vaccine that protects against more strains of pneumococcal disease, potentially reducing infections in older adults.
What could go wrong
This is an early Phase 1 trial with only 400 participants, so results may not apply to everyone. The main focus is safety, not yet proof of effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

400 people

The number who actually took part.

Started

Jul 2025

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria: 1.Generally healthy adults including those with preexisting stable disease determined to be eligible based on clinical assessment, medical history and clinical judgment. Key exclusion criteria: 1. History of microbiologically-proven invasive disease caused by Streptococcus pneumoniae 2. Previous vaccination with any licensed or investigational pneumococcal vaccine or planned receipt through study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pneumococcal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pneumococcal disease

Contacts and locations

Locations

  • Kaihua County Center For Disease Prevention and Control

    Kaihua, Zhejiang, 324300, China

  • Kaihua County Center For Disease Prevention and Control

    Quzhou, Zhejiang, 324300, China

  • Zhejiang provincial center for disease control and prevention

    Hangzhou, Zhejiang, 310051, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.